Personal Finance

Attention, Biotech Investors: Black Friday Is Already Here

Discount On Sale

Black Friday is just a few days away, which means that millions of consumers are gearing up to score huge discounts off their holiday shopping list. That's great, but we Fools get far more excited when high-quality stocks go on sale instead.

With that in mind, I scoured the biotech sector to identify stocks that are currently trading at highly discounted prices. Read on to see why I think the blue-light special is flashing on shares of Gilead Sciences (NASDAQ: GILD) , Illumina (NASDAQ: ILMN) , and Regeneron Pharmaceuticals (NASDAQ: REGN) .

Discount On Sale

Image source: Getty Images.

A victim of its own success

Gilead Sciences' sales and profits have been under pressure all year long, which has caused its stock to plunge. Shares have fallen nearly 40% from their 2015 highs, which has pulled its valuation down to absurdly cheap levels.

So why has this biotech giant's financials been heading in the wrong direction? The blame can be placed squarely on the shoulders of its hepatitis C franchise. A few years back, Gilead launched its hepatitis C cures Sovaldi and Harvoni to market, both of which saw instant success. Gilead's sales and profits immediately skyrocketed, allowing Gilead's stock to follow suit. However, recent competitive launches from AbbVie and Merck have forced management to give in on pricing in order to maintain market share. That has the market worried that this company's best days are behind it.

ILMN PE Ratio (TTM) Chart

ILMN P/E ratio (TTM) data by YCharts .

While Illumina's recent hiccup shouldn't be ignored, the total demand for gene-sequencing machines is likely to continue to grow rapidly over time. In fact, predictions currently for the market to reach $20 billion by 2020 and that figure could expand rapidly if the the company's investments in GRAIL and Helix work out.

As long as Illumina remains the top dog in the industry, then its future is looking bright.

Missing the forest for the trees

Regeneron Pharmaceuticals is another biotech giant that the markets have cast aside. Shares have dropped more than 26% since the start of the year in response to the company posting a string of negative headlines.

So what's gone wrong? First,data from a phase 2 study showed that its experimental compound rinucumab failed to improve upon the current standard of care treatments for neovascular age-related macular degeneration. Next, the Food and Drug Administration placed a clinical hold on its phase 2b study of fasinumab, a compound that is being researched with partner Teva Pharmaceuticals as a potential treatment for osteoarthritis pain and chronic low back pain. Finally, Regeneron and Sanofi announced that the FDA had rejected their submission for sarilumab for the treatment of rheumatoid arthritis due to manufacturing issues.

That's a lot of setbacks to throw at investors, so it is no wonder shares have headed in reverse year to date. However, I believe that this bad news is just a temporary setback, and that the company's long-term future is still looking bright. Here's why:

First, the problems with sarilumab and fasinumab appears to be fixable , so while these drugs are down, they are not out. Second, sales of the company's blockbuster drug Eylea continue to be strong , and its next-generation cholesterol-busting drug Praluent also looks like it is starting to pick up steam. Finally, an FDA decision on Dupixent, a potential blockbuster treatment for atopic dermatitis, is expected by the end of March. If it gets the green light, then investors enthusiasm for the company's shares could return.

In other words, Regeneron's future continues to look as bright as ever. That's why I think it's a great time to consider joining me as a shareholder .

10 stocks we like better than Gilead Sciences

When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor , has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Gilead Sciences wasn't one of them! That's right -- they think these 10 stocks are even better buys.

Click here to learn about these picks!

*Stock Advisor returns as of November 7, 2016

Brian Feroldi owns shares of Gilead Sciences and Regeneron Pharmaceuticals.Like this article? Follow him on Twitter where he goes by the handle@Longtermmindset or connect with him onLinkedInto see more articles like this.

The Motley Fool owns shares of and recommends Gilead Sciences and Illumina. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Personal Finance Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More